Major Depressive Disorder Treatments - Search News

US FDA approves new nasal spray for depression treatment

Hosted on MSN · 1d

FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.

FDA approves Spravato as monotherapy for adults with major depressive disorder

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.

Fox Business · 1d

J&J's ketamine-derived nasal spray approved by FDA to treat depression

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

20hon MSN

Using machine learning to predict how people diagnosed with major depressive disorder respond to treatment

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

Largest Study to Date Identifies Hundreds of Genes for Major Depression

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

GlobalData on MSN20h

J&J’s Spravato receives FDA label expansion for depression monotherapy

The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results